Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152516 · ClinicalTrials.gov registry record · Phase 3
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
NCT00152516 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 255 participants.
The verdict
NCT00152516, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
Study Summary
To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying cognition and behavior in children, and continue collection of safety/efficacy data.
Interventions
- DRUG levetiracetam (LEV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00152516
The ClinicalTrials.gov registry entry for NCT00152516 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which levetiracetam (LEV) is the first listed.
NCT00152516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00152516 about?
NCT00152516 is a clinical study titled "Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures". To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying cognition and behavior in children, and continue collection of safety/effi...
What is the current status of trial NCT00152516?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2004-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00152516?
The interventions under investigation include: levetiracetam (LEV) (DRUG).
Who is sponsoring clinical trial NCT00152516?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.